In Phase 3 CCTG IND.227/KEYNOTE-483 trial, KEYTRUDA plus chemotherapy also demonstrated statistically significant improvements in PFS and ORR compared to chemotherapy alone
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
Tremelimumab in combination with Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma (uHCC)
The increase in revenue and profits for the year was driven by business growth in the US market and growth in our subsidiaries in Canada & Brazil.
The Awards recognizes standout digital health & medical technology products and companies
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Marksans will continue to supply existing products until the end of 2023 to Teva's affiliates, ensuring high-quality standards
Acceptance based on results from the Phase 3 KEYNOTE-859 trial, which showed significant overall survival benefit in these patients with HER2-negative disease, regardless of PD-L1 expression
MoU signed between AIIA and University of Amrita Vishwa Vidhyapeetham for collaboration in the field of Research and Academics in Ayurveda
Bourgoin early development hub broadens offerings for oral solid dose formulations
Subscribe To Our Newsletter & Stay Updated
